Skip to main content
SpringerLink
Log in
Book cover

Follicular Lymphoma pp 83–99Cite as

Prognostic Factors in Follicular Lymphoma

  • Chapter
  • First Online:

  • 589 Accesses

Abstract

Follicular lymphoma (FL) is the most common indolent lymphoma. The majority of patients achieve a long-lasting remission with first-line induction therapy and have a good prognosis with median survival in excess of 20 years. However, approximately 20% exhibit early progression and have a poor prognosis. These are the patients who may benefit from novel treatment approaches. The challenge is in identifying them before progression. This chapter discusses current and developing approaches to define prognosis in follicular lymphoma. In current practice, prognostic indices based on readily available clinical information such as the Follicular Lymphoma International Prognostic Index (FLIPI) remain the most widely used prognostic tools. Developing approaches include measurement of total metabolic tumor volume (TMTV) using positron emission tomography (PET), clinicogenetic indices which integrate information about common genetic lesions in follicular lymphoma, and measures of the tumor microenvironment. The prognostic role of PET performed after induction treatment is now well defined, and evidence for this and future directions for research are discussed. The review is divided into two parts, the first focusing on clinical prognostic factors both at diagnosis and after treatment and the second discussing approaches based on emerging understanding of disease biology.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Project TIN-HsLPF. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–94.

    Article  Google Scholar 

  2. Decaudin D, Lepage E, Brousse N, Brice P, Harousseau J-L, Belhadj K, et al. Low-grade stage III–IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients—a study of the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1999;17(8):2499–505.

    Article  CAS  PubMed  Google Scholar 

  3. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–65.

    Article  CAS  PubMed  Google Scholar 

  4. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The follicular lymphoma international prognostic index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108(5):1504–8.

    Article  CAS  PubMed  Google Scholar 

  5. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–62.

    Article  PubMed  Google Scholar 

  6. Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. 2013;24(2):441–8.

    Article  CAS  PubMed  Google Scholar 

  7. Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111–22.

    Article  CAS  PubMed  Google Scholar 

  8. Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol. 2012;30(35):4317–22.

    Article  CAS  PubMed  Google Scholar 

  9. GLSG. Online calculator site: http://www.glsg.de/m7-flipi/. First published in [11].

  10. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15(3):1110–7.

    Article  CAS  PubMed  Google Scholar 

  11. Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–22.

    Article  CAS  PubMed  Google Scholar 

  12. Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424–35.

    Article  CAS  PubMed  Google Scholar 

  13. El-Galaly TC, Bilgrau AE, de Nully BP, Mylam KJ, Ahmad SA, Pedersen LM, et al. A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. Br J Haematol. 2015;169(3):435–44.

    Article  PubMed  Google Scholar 

  14. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417–23.

    Article  CAS  PubMed  Google Scholar 

  15. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725–32.

    Article  CAS  PubMed  Google Scholar 

  16. Farwell MD, Pryma DA, Mankoff DA. PET/CT imaging in cancer: current applications and future directions. Cancer. 2014;120(22):3433–45.

    Article  CAS  PubMed  Google Scholar 

  17. Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline metabolic tumor volume predicts outcome in high–tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34(30):3618–26.

    Article  PubMed  Google Scholar 

  18. Schöder H, Moskowitz C. Metabolic tumor volume in lymphoma: hype or hope? J Clin Oncol. 2016;34(30):3591–4.

    Article  PubMed  Google Scholar 

  19. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.

    Article  CAS  PubMed  Google Scholar 

  20. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol. 2015;33(23):2516–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Maurer MJ, Bachy E, Ghesquieres H, Ansell SM, Nowakowski GS, Thompson CA, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096–101.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, et al. Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials. J Clin Oncol. 2017;35(5):552–60.

    Article  PubMed  Google Scholar 

  23. Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29(23):3194–200.

    Article  PubMed  Google Scholar 

  24. Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C, et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol. 2014;25(2):442–7.

    Article  CAS  PubMed  Google Scholar 

  25. Trotman J, Luminari S, Boussetta S, Versari A, Dupuis J, Tychyj C, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014;1(1):e17–27.

    Article  PubMed  Google Scholar 

  26. Trotman J. Prognostic value of PET-CT after first-line immunochemotherapy for follicular lymphoma in the phase III gallium study. In: 14th International Conference On Malignant Lymphoma. Lugano; 2017.

    Google Scholar 

  27. Montoto S, Fitzgibbon J. Transformation of indolent B-cell lymphomas. J Clin Oncol. 2011;29(14):1827–34.

    Article  PubMed  Google Scholar 

  28. Wagner-Johnston ND, Link BK, Byrtek M, Dawson KL, Hainsworth J, Flowers CR, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126(7):851–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Casulo C, Burack WR, Friedberg JW. Transformed follicular non-Hodgkin lymphoma. Blood. 2015;125(1):40–7.

    Article  CAS  PubMed  Google Scholar 

  30. Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34(22):2575–82.

    Article  CAS  PubMed  Google Scholar 

  31. Kridel R, Sehn LH, Gascoyne RD. Pathogenesis of follicular lymphoma. J Clin Invest. 2012;122(10):3424–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Thiele J. WHO Classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: IARC; 2017.

    Google Scholar 

  33. Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, et al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol. 2012;156(2):225–33.

    Article  PubMed  Google Scholar 

  34. Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott MM, et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 2011;96(9):1327–34.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Liu Q, Salaverria I, Pittaluga S, Jegalian AG, Xi L, Siebert R, et al. Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol. 2013;37(3):333–43.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Louissaint A Jr, Ackerman AM, Dias-Santagata D, Ferry JA, Hochberg EP, Huang MS, et al. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood. 2012;120(12):2395–404.

    Article  CAS  PubMed  Google Scholar 

  37. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159–69.

    Article  CAS  PubMed  Google Scholar 

  39. Byers RJ, Sakhinia E, Joseph P, Glennie C, Hoyland JA, Menasce LP, et al. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood. 2008;111(9):4764–70.

    Article  CAS  PubMed  Google Scholar 

  40. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106(6):2169–74.

    Article  CAS  PubMed  Google Scholar 

  41. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood. 2010;115(2):289–95.

    Article  CAS  PubMed  Google Scholar 

  42. Ame-Thomas P, Hoeller S, Artchounin C, Misiak J, Braza MS, Jean R, et al. CD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cells. Blood. 2015;125(15):2381–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Yang ZZ, Grote DM, Ziesmer SC, Xiu B, Novak AJ, Ansell SM. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival. Blood Cancer J. 2015;5(2):e281.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017;129(4):473–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Morin R, Mendez-Lago M, Mungall A, Goya R, Mungall K, Corbett R, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Okosun J, Bodor C, Wang J, Araf S, Yang CY, Pan C, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 2014;46(2):176–81.

    Article  CAS  PubMed  Google Scholar 

  47. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471(7337):189–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. García-Ramírez I, Tadros S, González-Herrero I, Martín-Lorenzo A, Rodríguez-Hernández G, Moore D, et al. Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. Blood. 2017;129(19):2645–56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Bodor C, Grossmann V, Popov N, Okosun J, O’Riain C, Tan K, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122(18):3165–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Cheung KJ, Johnson NA, Affleck JG, Severson T, Steidl C, Ben-Neriah S, et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res. 2010;70(22):9166–74.

    Article  CAS  PubMed  Google Scholar 

  51. Launay E, Pangault C, Bertrand P, Jardin F, Lamy T, Tilly H, et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia. 2012;26(3):559–62.

    Article  CAS  PubMed  Google Scholar 

  52. Schmidt J, Gong S, Marafioti T, Mankel B, Gonzalez-Farre B, Balague O, et al. Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood. 2016;128(8):1101–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. O’Shea D, O’Riain C, Taylor C, Waters R, Carlotti E, MacDougall F, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood. 2008;112(8):3126–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  54. Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 2015;125(4):658–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Huet S, Szafer-Glusman E, Tesson B, Xerri L, Fairbrother WJ, Mukhyala K, et al. BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab. Am J Hematol. 2017;92(6):515–9.

    Article  CAS  PubMed  Google Scholar 

  56. Weigert O, Weinstock DM. The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. Blood. 2017;130(13):1491–8.

    Article  CAS  PubMed  Google Scholar 

  57. Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016;128(8):1112–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Huet S, Tesson B, Jais J-P, Feldman AE, Magnano L, Thomas E, et al. A gene-expression profiling score for outcome predniction in patients with follicular lymphoma: a retrospective analysis on three international cohorts. Lancet Oncol. 2018;19(4):549–61.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, et al. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009;114(4):826–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Diaz-Alderete A, Doval A, Camacho F, Verde L, Sabin P, Arranz-Saez R, et al. Frequency of BCL2 and BCL6 translocations in follicular lymphoma: relation with histological and clinical features. Leuk Lymphoma. 2008;49(1):95–101.

    Article  CAS  PubMed  Google Scholar 

  61. Katzenberger T, Ott G, Klein T, Kalla J, Muller-Hermelink HK, Ott MM. Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol. 2004;165(2):481–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Bosga-Bouwer AG, van Imhoff GW, Boonstra R, van der Veen A, Haralambieva E, van den Berg A, et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood. 2003;101(3):1149–54.

    Article  CAS  PubMed  Google Scholar 

  63. Miyaoka M, Kikuti YY, Carreras J, Ikoma H, Hiraiwa S, Ichiki A, et al. Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Mod Pathol. 2018;31(2):313–26.

    Article  CAS  PubMed  Google Scholar 

  64. Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, et al. PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin lymphoma study. Blood. 2016;127(12):1531–8.

    Article  CAS  PubMed  Google Scholar 

  65. Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol. 2004;22(8):1460–8.

    Article  PubMed  Google Scholar 

  66. Moos M, Schulz R, Martin S, Benner A, Haas R. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin’s lymphoma. Leukemia. 1998;12(12):1971–6.

    Article  CAS  PubMed  Google Scholar 

  67. Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, et al. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res. 2014;20(24):6398–405.

    Article  CAS  PubMed  Google Scholar 

  68. van Oers MH, Tonnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, et al. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol. 2010;28(13):2246–52.

    Article  PubMed  CAS  Google Scholar 

  69. Luminari S, Galimberti S, Versari A, Biasoli I, Anastasia A, Rusconi C, et al. Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Haematologica. 2016;101(2):e66–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Tasmania and Department of Haematology, Royal Hobart Hospital, Hobart, TAS, Australia

    Anna Johnston

  2. University of Sydney and Department of Haematology, Concord Repatriation Hospital, Sydney, NSW, Australia

    Judith Trotman

Authors
  1. Anna Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Judith Trotman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Judith Trotman .

Editor information

Editors and Affiliations

  1. Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Nathan H. Fowler

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Johnston, A., Trotman, J. (2020). Prognostic Factors in Follicular Lymphoma. In: Fowler, N. (eds) Follicular Lymphoma. Springer, Cham. https://doi.org/10.1007/978-3-030-26211-2_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-26211-2_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-26210-5

  • Online ISBN: 978-3-030-26211-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation